{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"OtherAbstract": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "SpaceFlightMission": [], "KeywordList": [], "InvestigatorList": [], "PMID": "6708393", "DateCompleted": {"Year": "1984", "Month": "05", "Day": "18"}, "DateRevised": {"Year": "2019", "Month": "07", "Day": "11"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "0023-2173", "JournalIssue": {"Volume": "62", "Issue": "2", "PubDate": {"Year": "1984", "Month": "Jan", "Day": "16"}}, "Title": "Klinische Wochenschrift", "ISOAbbreviation": "Klin Wochenschr"}, "ArticleTitle": "Influence of digitalis and diuretics on ouabain binding sites on human erythrocytes.", "Pagination": {"StartPage": "87", "EndPage": "92", "MedlinePgn": "87-92"}, "Abstract": {"AbstractText": ["It has been reported that during chronic treatment with digitalis, the number of digitalis binding sites is increased in human erythrocytes [22]. From this finding a tachyphylaxis for cardiac glycosides has been postulated. We reinvestigated this problem in several groups of patients. The number of 3H-ouabain binding sites per erythrocyte in control persons (group I) was 214 +/- 60, n = 43 (means +/- SD). The dissociation constant (KD) was 1.8 +/- 0.5 nM. Thirteen patients (group II) taking cardiac glycosides only, for at least 6 months, had 281 +/- 99 (p less than 0.05) ouabain binding sites per single red cell, KD = 1.8 +/- 0.7 nM. Group III (34 patients) took digitalis for more than 6 months and diuretics for at least 3 months (352 +/- 126 (p less than 0.001), KD = 1.6 +/- 0.6). Twenty-three of these (group IV) were taking a combination with \"K+-saving\" diuretics (336 +/- 194 (p less than 0.01), KD = 1.6 +/- 0.5) and (group V, 11 patients) a combination with \"K+-losing\" diuretics (462 +/- 133 (p less than 0.001), KD = 1.4 +/- 0.4). Nine patients (group VI) had a chronic hypokalemia, mainly due to taking furosemide (437 +/- 98 (p less than 0.001), KD = 1.5 +/- 0.4). Four control persons took 50 mg hydrochlorothiazide daily for more than 4 months without measurable K+-losses and without changes in ouabain binding sites. It is concluded from these findings that diuretic treatment with chronic hypokalemia in addition to digitalis is accompanied by a significant increase in ouabain binding sites in human red cells.(ABSTRACT TRUNCATED AT 250 WORDS)"]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Erdmann", "ForeName": "E", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Werdan", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Krawietz", "ForeName": "W", "Initials": "W"}], "PublicationTypeList": ["Clinical Trial", "Controlled Clinical Trial", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Klin Wochenschr", "NlmUniqueID": "2985205R", "ISSNLinking": "0023-2173"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Diuretics"}, {"RegistryNumber": "5ACL011P69", "NameOfSubstance": "Ouabain"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["drug effects"], "DescriptorName": "Binding Sites"}, {"QualifierName": [], "DescriptorName": "Digitalis"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Diuretics"}, {"QualifierName": ["drug effects"], "DescriptorName": "Erythrocytes"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ouabain"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "N Engl J Med. 1978 Sep 7;299(10):501-4", "ArticleIdList": ["683206"]}, {"Citation": "Br J Clin Pharmacol. 1981 Jun;11(6):565-70", "ArticleIdList": ["6268133"]}, {"Citation": "Br J Clin Pharmacol. 1979 Aug;8(2):135-42", "ArticleIdList": ["486290"]}, {"Citation": "Naunyn Schmiedebergs Arch Pharmacol. 1977 Dec;301(1):39-47", "ArticleIdList": ["146167"]}, {"Citation": "Clin Sci (Lond). 1983 Feb;64(2):177-82", "ArticleIdList": ["6822054"]}, {"Citation": "Klin Wochenschr. 1981 Dec 15;59(24):1323-32", "ArticleIdList": ["6275162"]}, {"Citation": "Clin Sci (Lond). 1983 Feb;64(2):167-76", "ArticleIdList": ["6822053"]}, {"Citation": "Br J Clin Pharmacol. 1979 Aug;8(2):125-34", "ArticleIdList": ["486289"]}, {"Citation": "Eur J Pharmacol. 1976 May;37(1):189-91", "ArticleIdList": ["132355"]}, {"Citation": "J Physiol. 1975 Oct;251(3):671-82", "ArticleIdList": ["127037"]}, {"Citation": "Nature. 1981 Oct 29;293(5835):739-41", "ArticleIdList": ["6270573"]}, {"Citation": "Acta Biol Med Ger. 1977;36(5-6):879-83", "ArticleIdList": ["602591"]}, {"Citation": "Klin Wochenschr. 1976 Apr 15;54(8):383-7", "ArticleIdList": ["1271692"]}, {"Citation": "Arch Biochem Biophys. 1971 Jul;145(1):121-5", "ArticleIdList": ["4256440"]}, {"Citation": "Br J Clin Pharmacol. 1979 Aug;8(2):115-24", "ArticleIdList": ["486288"]}, {"Citation": "Physiol Rev. 1965 Jul;45:596-617", "ArticleIdList": ["14337569"]}, {"Citation": "Klin Wochenschr. 1981 Dec 15;59(24):1333-43", "ArticleIdList": ["6275163"]}, {"Citation": "Klin Wochenschr. 1975 Feb 1;53(3):125-8", "ArticleIdList": ["1142709"]}, {"Citation": "Ann N Y Acad Sci. 1974;242(0):471-88", "ArticleIdList": ["4279600"]}, {"Citation": "Biochem Biophys Res Commun. 1983 Feb 28;111(1):319-25", "ArticleIdList": ["6830597"]}, {"Citation": "Arch Int Pharmacodyn Ther. 1978 May;233(1):53-64", "ArticleIdList": ["28701"]}, {"Citation": "Arch Biochem Biophys. 1969 Oct;134(1):48-52", "ArticleIdList": ["4242088"]}, {"Citation": "Scand J Clin Lab Invest. 1974 Feb;33(1):11-6", "ArticleIdList": ["4827753"]}], "ReferenceList": []}], "History": [{"Year": "1984", "Month": "1", "Day": "16"}, {"Year": "1984", "Month": "1", "Day": "16", "Hour": "0", "Minute": "1"}, {"Year": "1984", "Month": "1", "Day": "16", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["6708393", "10.1007/BF01769668"]}}]}